46.98
0.72%
-0.34
After Hours:
46.97
-0.010
-0.02%
Crispr Therapeutics Ag stock is traded at $46.98, with a volume of 911.92K.
It is down -0.72% in the last 24 hours and down -1.55% over the past month.
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for to treat Type 1 diabetes.
See More
Previous Close:
$47.32
Open:
$46.94
24h Volume:
911.92K
Relative Volume:
0.78
Market Cap:
$4.03B
Revenue:
$170.10M
Net Income/Loss:
$-153.61M
P/E Ratio:
-10.51
EPS:
-4.47
Net Cash Flow:
$-272.35M
1W Performance:
+0.51%
1M Performance:
-1.55%
6M Performance:
-31.07%
1Y Performance:
+3.50%
Crispr Therapeutics Ag Stock (CRSP) Company Profile
Name
Crispr Therapeutics Ag
Sector
Industry
Phone
(617) 315-4600
Address
BAARERSTRASSE 14, ZUG
Crispr Therapeutics Ag Stock (CRSP) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Feb-15-24 | Initiated | Wolfe Research | Peer Perform |
Dec-11-23 | Downgrade | TD Cowen | Market Perform → Underperform |
Oct-17-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
Sep-27-23 | Initiated | Mizuho | Buy |
Aug-17-23 | Upgrade | Citigroup | Neutral → Buy |
May-30-23 | Initiated | William Blair | Outperform |
Apr-13-23 | Initiated | Cantor Fitzgerald | Overweight |
Mar-21-23 | Initiated | Bernstein | Mkt Perform |
Mar-17-23 | Initiated | Bryan Garnier | Buy |
Mar-07-23 | Initiated | Robert W. Baird | Neutral |
Oct-11-22 | Initiated | Morgan Stanley | Underweight |
Aug-09-22 | Downgrade | Barclays | Overweight → Equal Weight |
Jun-23-22 | Downgrade | Evercore ISI | Outperform → In-line |
Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
Apr-28-22 | Initiated | Credit Suisse | Neutral |
Dec-07-21 | Initiated | Cowen | Market Perform |
Oct-19-21 | Initiated | SVB Leerink | Outperform |
Jun-14-21 | Upgrade | Citigroup | Sell → Neutral |
Apr-21-21 | Upgrade | Jefferies | Hold → Buy |
Mar-04-21 | Initiated | JMP Securities | Mkt Outperform |
Dec-10-20 | Reiterated | Chardan Capital Markets | Buy |
Dec-10-20 | Downgrade | Jefferies | Buy → Hold |
Dec-10-20 | Reiterated | Needham | Buy |
Dec-07-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
Oct-05-20 | Initiated | BofA Securities | Buy |
Jul-28-20 | Reiterated | Needham | Buy |
Jul-14-20 | Initiated | SunTrust | Buy |
Jun-15-20 | Reiterated | Canaccord Genuity | Buy |
Mar-05-20 | Initiated | Stifel | Hold |
Feb-03-20 | Downgrade | Evercore ISI | Outperform → In-line |
Nov-19-19 | Upgrade | William Blair | Mkt Perform → Outperform |
Nov-12-19 | Upgrade | Oppenheimer | Perform → Outperform |
Aug-01-19 | Initiated | Jefferies | Buy |
Jul-26-19 | Initiated | Canaccord Genuity | Buy |
Jun-10-19 | Initiated | ROTH Capital | Buy |
Apr-12-19 | Initiated | Evercore ISI | Outperform |
Mar-14-19 | Initiated | William Blair | Mkt Perform |
Jan-28-19 | Downgrade | Goldman | Buy → Neutral |
Jan-22-19 | Downgrade | Citigroup | Neutral → Sell |
View All
Crispr Therapeutics Ag Stock (CRSP) Latest News
Dimensional Fund Advisors LP Grows Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Where are the Opportunities in (CRSP) - Stock Traders Daily
CRISPR Therapeutics AG (NASDAQ:CRSP) Stock Holdings Increased by Scientech Research LLC - MarketBeat
Wall Street SWOT: CRISPR Therapeutics stock navigates gene therapy frontier - Investing.com
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know - Yahoo Finance
First Week of November 15th Options Trading For CRISPR Therapeutics - Nasdaq
Take off with CRISPR Therapeutics AG (CRSP): Get ready for trading - SETE News
Vertex taps Lonza to help produce global supply of cutting-edge CRISPR therapy Casgevy - FiercePharma
Farallon Capital Management LLC Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Farallon Capital Management LLC Invests $28.63 Million in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Adverum Biotechnologies (NASDAQ:ADVM) & CRISPR Therapeutics (NASDAQ:CRSP) Head to Head Comparison - Defense World
Itau Unibanco Holding S.A. Purchases Shares of 646 CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
CRISPR Therapeutics AG (NASDAQ:CRSP) Position Decreased by Integral Health Asset Management LLC - Defense World
Integral Health Asset Management LLC Has $8.10 Million Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by State of New Jersey Common Pension Fund D - Defense World
CRISPR Therapeutics (NASDAQ:CRSP) shareholders have endured a 59% loss from investing in the stock three years ago - Yahoo Finance
3 Dirt Cheap Stocks to Buy Right Now - The Motley Fool
Blair William & Co. IL Cuts Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Blair William & Co. IL Sells 12,921 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - MSN
Choreo LLC Buys Shares of 4,047 CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
CRISPR Therapeutics AG (CRSP) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance
1 Biotech Stock Down 62% to Buy and Hold - AOL
CRISPR Therapeutics AG (NASDAQ:CRSP) Holdings Lifted by E Fund Management Co. Ltd. - Defense World
1 growth stock that could skyrocket over the next 10 years - Yahoo Finance UK
CRISPR Therapeutics AG (CRSP) Dips More Than Broader Market: What You Should Know - MSN
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Consensus Rating of "Hold" from Brokerages - MarketBeat
Down 21% This Year, Is CRISPR Therapeutics Stock Still a Buy? - The Motley Fool
CRISPR Therapeutics AG (NASDAQ:CRSP) Receives Average Recommendation of “Hold” from Analysts - Defense World
(CRSP) Trading Advice - Stock Traders Daily
Shariaportfolio Inc. Buys New Stake in CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics: Prepare To Be Bored (NASDAQ:CRSP) - Seeking Alpha
Oppenheimer & Co. Inc. Buys 1,958 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
7 Top Gene-Editing Stocks to Buy | Investing - U.S News & World Report Money
National Bank of Canada FI Has $46,000 Stock Holdings in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Wedbush Securities Inc. Has $307,000 Stock Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Headlands Technologies LLC Takes Position in CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Principal Financial Group Inc. Sells 33,418 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - Defense World
Principal Financial Group Inc. Sells 33,418 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres - Seeking Alpha
1 Biotech Stock Down 62% to Buy and Hold - The Globe and Mail
Looking for Stock Bargains With Room to Run? Try This. - The Motley Fool
Private Advisor Group LLC Buys 64,076 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) - MarketBeat
CRISPR Therapeutics AG (CRSP) Laps the Stock Market: Here's Why - Yahoo Finance
Global Genetic Engineering Market Size To Worth USD 8.95 Billion By 2033 | CAGR Of 20.82% - GlobeNewswire Inc.
Gene Editing Therapeutics Market Forecast 2024-2029: A $1 Billion Market by 2029, with a Forecasted CAGR of 147% - GlobeNewswire Inc.
CRISPR Therapeutics AG (CRSP): Among the Worst ARK Stocks According to Short Sellers - MSN
What's Going On With Crispr Therapeutics Stock Thursday? - MSN
Who are the leading innovators in CRISPR vectors for the pharmaceutical industry? - Pharmaceutical Technology
CRISPR Therapeutics - FiercePharma
10 Worst ARK Stocks To Buy According To Short Sellers - Insider Monkey
Crispr Therapeutics Ag Stock (CRSP) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):